Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Branded Generics Escape Indian Trade Margin Limits

This article was originally published in PharmAsia News

Executive Summary

Generic drugs with brand names in India could be excluded from the government's proposal to restrict trade margins. The exclusion would cover drug makers such as Cadita Healthcare, GlaxoSmithKline, Nicholas Piramal and Ranbaxy, all of which sell generics under brand names rather than chemical names. Those brand names place the drugs in another category under Indian law. Makers of the branded generics allow retail pharmacies a trade margin as high as 29 times the manufactured price. (Click here for more
UsernamePublicRestriction

Register

SC068609

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel